Skip to main content
Premium Trial:

Request an Annual Quote

NuGen Technologies Raises $7.8M in VC Financing; Mike Hunkapiller Joins Board

NEW YORK, March 21 (GenomeWeb News) - NuGen Technologies said today that it has raised $7.8 million in private-equity funding.


The company will use the money to accelerate its technology development and expand global distribution for its RNA amplification and detection systems for gene expression research, NuGen said.


Alloy Ventures led the financing round, and existing NuGen investors Sutter Hill Ventures, Radius Ventures, and The Band of Angels also participated.


NuGen also said that Michael Hunkapiller, former president and general manager of Applied Biosystems, Celera founder, and Applera senior vice president, has joined the company's board of directors.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.